Park Tai Hwan, Hong Keun-Sik, Cho Yong-Jin, Ryu Wi-Sun, Kim Dong-Eog, Park Man-Seok, Choi Kang-Ho, Kim Joon-Tae, Kang Jihoon, Kim Beom-Joon, Han Moon-Ku, Lee Jun, Cha Jae-Kwan, Kim Dae-Hyun, Kim Jae Guk, Lee Soo Joo, Kwon Jee-Hyun, Kim Wook-Joo, Shin Dong-Ick, Yum Kyu Sun, Sohn Sung Il, Hong Jeong-Ho, Choi Jay Chol, Lee Byung-Chul, Yu Kyung-Ho, Oh Mi-Sun, Park Jong-Moo, Kang Kyusik, Lee Kyungbok, Lee Sang-Hwa, Jeong Hae-Bong, Park Kwang-Yeol, Lee Ji Sung, Lee Juneyoung, Gorelick Philip B, Bae Hee-Joon
Department of Neurology Seoul Medical Center Seoul Korea.
Department of Neurology Ilsan Paik Hospital, Inje University Goyang Korea.
J Am Heart Assoc. 2025 Mar 4;14(5):e035218. doi: 10.1161/JAHA.124.035218. Epub 2025 Feb 19.
This study aims to evaluate temporal trends of advanced treatments and related clinical outcomes of ischemic stroke through a decade-long trend analysis, using data from a comprehensive, national, multicenter registry. We also seek to identify areas in need of improvement.
This analysis involved patients with ischemic stroke or transient ischemic attack registered prospectively in the CRCS-K-NIH (Clinical Research Center for Stroke in Korea-National Institute of Health) registry between 2011 and 2020. We examined temporal trends in risk factors, pathogenetic subtypes, acute management strategies, and outcomes for up to 1 year following a stroke. Generalized linear mixed models were used to account for center clustering. The average age of 77 662 patients increased 2.2 years in men and 2.4 years in women over the 10-year follow-up. Notably, in-hospital neurological deterioration, 3-month and 1-year mortality rate, and cumulative incidence of recurrent stroke within 1-year decreased over time after adjustments for age, sex, and initial stroke severity (<0.01). However, functional outcomes at 3 months and 1 year remained unchanged. Endovascular thrombectomy increased from 5.4% in 2011 to 10.6% in 2020. Use of anticoagulants for atrial fibrillation, dual antiplatelet therapy, statins, and stroke unit care also increased. Contrarily, the rate of intravenous thrombolysis showed a slight decline.
This study points to a reduction in death and risk of recurrent stroke over the past decade, paralleling enhancement in acute and preventive stroke management. Nevertheless, the decline in the use of intravenous thrombolysis and the lack of improvement in functional outcomes following stroke are concerning trends that warrant thorough investigation.
本研究旨在通过长达十年的趋势分析,利用来自一个全面的、全国性的、多中心登记处的数据,评估缺血性卒中的先进治疗方法的时间趋势及相关临床结局。我们还试图确定需要改进的领域。
本分析纳入了2011年至2020年间前瞻性登记在CRCS-K-NIH(韩国国立卫生研究院卒中临床研究中心)登记处的缺血性卒中和短暂性脑缺血发作患者。我们研究了卒中后长达1年的危险因素、致病亚型、急性管理策略和结局的时间趋势。采用广义线性混合模型来考虑中心聚类情况。在10年的随访中,77662例患者的平均年龄男性增加了2.2岁,女性增加了2.4岁。值得注意的是,在校正年龄、性别和初始卒中严重程度后,院内神经功能恶化、3个月和1年死亡率以及1年内复发性卒中的累积发生率随时间下降(<0.01)。然而,3个月和1年时的功能结局保持不变。血管内血栓切除术从2011年的5.4%增加到2020年的10.6%。用于心房颤动的抗凝剂、双重抗血小板治疗、他汀类药物和卒中单元护理的使用也有所增加。相反,静脉溶栓率略有下降。
本研究表明,在过去十年中,死亡和复发性卒中风险有所降低,这与急性和预防性卒中管理的改善并行。尽管如此,静脉溶栓使用的下降以及卒中后功能结局缺乏改善是令人担忧的趋势,值得深入调查。